Before taking its repurposed diabetes drug candidate into a phase 2 lupus trial, Conduit Pharmaceuticals is tapping Charles ...

Insilico Medicine ( “Insilico”) , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today ...

IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company's FDA discussions confirmed that relapse-free survival ...

Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without ...

Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing Charles River's immunology expertise to refine study ...

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.

Q4 2024 Earnings Call Transcript February 11, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.63, ...

Biohaven's NDA for Troriluzole was accepted by the FDA, potentially leading to approval in Q3 2025. Click here to find out ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solution ...

Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late-stage anticoagulant, to its ...